Volume 152, Issue 6, Pages 1169-1178 (December 2017) Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD  Fernando J. Martinez, MD, FCCP, Leonardo M. Fabbri, MD, FCCP, Gary T. Ferguson, MD, FCCP, Chad Orevillo, MPH, Patrick Darken, PhD, Ubaldo J. Martin, MD, Colin Reisner, MD, FCCP  CHEST  Volume 152, Issue 6, Pages 1169-1178 (December 2017) DOI: 10.1016/j.chest.2017.07.007 Copyright © 2017 The Authors Terms and Conditions

Figure 1 Relationship between CAT and mMRC dyspnea grade (pooled ITT population). CAT = COPD Assessment Test; mMRC = modified Medical Research Council. CHEST 2017 152, 1169-1178DOI: (10.1016/j.chest.2017.07.007) Copyright © 2017 The Authors Terms and Conditions

Figure 2 Relationship between baseline CAT score and the magnitude of improvement in (A) morning predose trough FEV1 or (B) peak FEV1 at week 24 observed in the GFF MDI group compared with monocomponent MDIs or placebo MDI. All treatment differences for the GFF MDI vs individual monocomponent MDIs and the placebo MDI were associated with P < .05. FF = formoterol fumarate; GFF = glycopyrrolate/formoterol fumarate; GP = glycopyrrolate; ITT = intent to treat; LSM = least squares mean; MDI = metered dose inhaler. See Figure 1 legend for expansion of other abbreviations. CHEST 2017 152, 1169-1178DOI: (10.1016/j.chest.2017.07.007) Copyright © 2017 The Authors Terms and Conditions

Figure 3 Relationship between baseline CAT score and (A) the magnitude of improvement in change from baseline in the SGRQ total score at week 24 and (B) the proportion of patients achieving the MCID for SGRQ total score at week 24 for GFF MDI vs comparator (95% CI). MCID was defined as a four-unit improvement in SGRQ total score. *P < .05; †P < .01. MCID = minimum clinically important difference; SGRQ = St. George’s Respiratory Questionnaire. See Figure 1 and 2 legends for expansion of other abbreviations. CHEST 2017 152, 1169-1178DOI: (10.1016/j.chest.2017.07.007) Copyright © 2017 The Authors Terms and Conditions

Figure 4 Time to first moderate or severe exacerbation, hazard ratio for GFF MDI vs comparator (95% CI) stratified by baseline CAT score. Data shown are for patients with evaluable data for each end point. *P < .05; †P < .01. HR = hazard ratio. See Figure 1 and 2 legends for expansion of other abbreviations. CHEST 2017 152, 1169-1178DOI: (10.1016/j.chest.2017.07.007) Copyright © 2017 The Authors Terms and Conditions